These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 28331351)

  • 21. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
    Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
    Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exenatide Once Weekly for Management of Type 2 Diabetes: A Review.
    Inaishi J; Saisho Y
    Clin Pharmacol; 2022; 14():19-26. PubMed ID: 35422660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists.
    Lindamood CA; Taylor JR
    Clin Ther; 2015 Mar; 37(3):483-93. PubMed ID: 25659912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Plethora of GLP-1 Agonists: Decisions About What to Use and When.
    Samson SL; Garber AJ
    Curr Diab Rep; 2016 Dec; 16(12):120. PubMed ID: 27766579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.
    Singh S; Wright EE; Kwan AY; Thompson JC; Syed IA; Korol EE; Waser NA; Yu MB; Juneja R
    Diabetes Obes Metab; 2017 Feb; 19(2):228-238. PubMed ID: 27717130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis.
    Jiang Y; Liu J; Chen X; Yang W; Jia W; Wu J
    Adv Ther; 2021 Mar; 38(3):1470-1482. PubMed ID: 33582976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes.
    Heimbürger SM; Brønden A; Johansen NJ; Dejgaard TF; Vilsbøll T; Knop FK
    Expert Opin Pharmacother; 2019 Apr; 20(5):501-510. PubMed ID: 30730773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.
    Zaccardi F; Htike ZZ; Webb DR; Khunti K; Davies MJ
    Ann Intern Med; 2016 Jan; 164(2):102-13. PubMed ID: 26642233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Kayaniyil S; Lozano-Ortega G; Bennett HA; Johnsson K; Shaunik A; Grandy S; Kartman B
    Diabetes Ther; 2016 Mar; 7(1):27-43. PubMed ID: 26886440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
    Chun JH; Butts A
    JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
    Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C
    J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
    Chun JH; Butts A
    JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
    Yuan S; Wu Y
    Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes.
    Marso SP; Hardy E; Han J; Wang H; Chilton RJ
    Diabetes Ther; 2018 Apr; 9(2):551-564. PubMed ID: 29397532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Patel D
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes.
    Genovese S; Mannucci E; Ceriello A
    Adv Ther; 2017 Aug; 34(8):1791-1814. PubMed ID: 28674957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exenatide: pharmacokinetics, clinical use, and future directions.
    Knop FK; Brønden A; Vilsbøll T
    Expert Opin Pharmacother; 2017 Apr; 18(6):555-571. PubMed ID: 28085521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
    Shaefer CF; Kushner P; Aguilar R
    Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.